Hemonetics (HAE) Q4 2026: Plasma Share Up High-Single Digits, Clearing $153M Portfolio Overhang
Hemonetics exits FY26 with its plasma franchise gaining high-single-digit share and clearing a $153 million portfolio transition drag, setting up a less encumbered growth runway for FY27. Hospital and plasma platforms are now the central earnings engines, while interventional technologies (IVT) turns the corner with headwinds lapping and new launches on deck. Management’s guidance is grounded in controllable drivers, with upside potential if plasma collection volumes or innovation adoption accelerate.
Summary
- Plasma Franchise Strengthens: Share gains and Persona Plus rollout reinforce plasma’s role as the growth and cash flow anchor.
- IVT Inflection Point: Headwinds from OEM and PFA now largely lapped, with renewed optimism for FY27 growth.
- Clean Year Ahead: Portfolio transitions and CSL drag now behind, positioning HAE for more transparent and consistent results.
Business Overview
Hemonetics develops and sells medical devices and consumables for blood and plasma collection, hospital blood management, and interventional procedures. Revenue is generated from three main segments: Plasma (equipment and disposables for plasma collection centers), Hospital (blood management and vascular closure devices), and Blood Center (products for blood banks). Plasma is the largest and highest-margin business, while hospital and IVT are targeted for future growth. The company’s model is driven by recurring revenue from disposables and innovation-driven market share gains.
Performance Analysis
Hemonetics delivered a Q4 marked by 9% organic revenue growth ex-CSL transitions, with plasma and hospital segments as the primary drivers. Plasma revenue grew 13% organic ex-CSL, supported by share gains, innovation, and stable market fundamentals, despite a modest sequential volume dip and lapping of prior price gains. Hospital revenue increased 8%, propelled by record blood management results, especially in TEG6S and transfusion management, which together contributed double-digit growth.
IVT revenue declined 10% for the quarter, but the company emphasized that 80% of the year’s IVT decline stemmed from now-lapped OEM and PFA headwinds. Gross margin for the year expanded 280 basis points to 60.3%, driven by portfolio transformation and volume leverage, though Q4 margins were pressured by tariffs and higher benefit costs. Free cash flow conversion reached 89% for the year, enabling $175 million in share repurchases and $61 million for the Vivashore acquisition, while maintaining a net leverage ratio of 2.73x EBITDA.
- Hospital Segment Momentum: Blood management technologies posted record results, with broad-based adoption in TEG6S and strong European traction.
- Plasma Share and Innovation: High-single-digit share gains in the US and double-digit growth in Europe, with Persona Plus rollout providing additional yield and pricing leverage.
- IVT Turning Point: Sequential growth in electrophysiology and stabilization of sensor-guided tech, with new product launches (MVP XL, Percocel Elite) set to re-energize the business.
Portfolio transitions and the CSL contract drag are now fully cycled, giving HAE a “clean print” heading into FY27 and reducing the need for adjusted metrics and asterisks in future quarters.
Executive Commentary
"Fiscal 26 marked the culmination of our long-range plan for transformational growth, whereby we fundamentally repositioned humanetics into a more focused, higher quality, and more resilient company with significantly stronger growth margins and cash flow."
Chris Simon, CEO
"Cash generation continues to be a defining strength of the business and a key source of strategic flexibility. With our major device investments and productivity initiatives largely behind us, the business has returned to a strong and sustainable cash flow profile."
James Dureka, CFO
Strategic Positioning
1. Plasma Platform as Core Growth Engine
Plasma remains HAE’s most resilient and profitable business, with share gains, innovation adoption (Persona Plus, yield-enhancing platform), and robust global demand for immunoglobulin therapies driving results. Management’s mid-single-digit growth guide is anchored in controllable drivers (share, yield, price), with upside if collection volumes or adoption outpace conservative assumptions.
2. Hospital and Blood Management Expansion
Hospital segment is now a material contributor, with TEG6S and transfusion management solutions gaining traction in both US and Europe. The launch of new cartridges and expanded indications (Vascade MVP XL) are broadening the addressable market and supporting high-margin growth.
3. IVT Repositioning and Pipeline Execution
IVT headwinds from OEM and PFA are now largely lapped, and the commercial team has been rebuilt with new tools and products. The upcoming launch of Percocel Elite (pending FDA) and expanded MVP XL label are positioned to drive a return to growth in vascular closure, especially in electrophysiology (EP), where procedure volumes are set to rebound.
4. Portfolio Rationalization and Margin Expansion
Divestiture of whole blood and exit from low-growth product lines have structurally improved gross and operating margins. Management is now focused on scaling high-return franchises and leveraging operational efficiency, with targeted R&D and commercial investments to support future launches.
5. Capital Allocation and Financial Flexibility
Strong free cash flow supports both organic reinvestment and shareholder returns, with a balanced approach to buybacks, M&A (Vivashore), and deleveraging. The refinancing of convertible notes and disciplined working capital management further enhance flexibility.
Key Considerations
This quarter marks a strategic transition for Hemonetics, as legacy portfolio headwinds clear and the company pivots to a more innovation-led, recurring revenue model. Investors should focus on the pace of plasma innovation adoption, the hospital segment’s ability to sustain high margins, and the IVT turnaround’s durability.
Key Considerations:
- Plasma Innovation Rollout: Persona Plus offers a 5% yield improvement over prior Persona, driving value for customers and pricing leverage for HAE.
- IVT Growth Catalysts: New product launches (MVP XL, Percocel Elite) and lapping of OEM/PFA headwinds set the stage for a return to growth in FY27.
- Margin Structure: Portfolio mix shift and operational leverage support further margin expansion, though tariffs and benefit costs are built into guidance.
- Clean Financials: With CSL and portfolio transitions behind, reported results will better reflect the underlying earnings power and growth trajectory.
Risks
Plasma market cyclicality and innovation adoption rates remain key variables, with management conservatively excluding volume upside from guidance. Tariff exposure (assumed at 15% in FY27), higher benefit costs, and ongoing investment in launches could pressure margins if not offset by mix and volume. IVT recovery is dependent on successful execution of new launches and stabilization of underlying procedure volumes.
Forward Outlook
For Q1 FY27, Hemonetics guided to:
- Revenue growth of 4% to 7% reported, 3% to 6% organic (adjusted for 53rd week and FX)
- Adjusted operating margin expansion of 50 to 100 basis points year over year
For full-year 2027, management maintained guidance:
- Revenue growth of 4% to 7% reported, 3% to 6% organic
- Adjusted EPS growth in line with reported revenue
- Free cash flow conversion of approximately 80%
Management emphasized:
- Guidance is based on controllable drivers (share, yield, price), with no volume upside or Percocel Elite revenue included
- Potential for upside if plasma collection volumes or innovation adoption outpace assumptions
Takeaways
Hemonetics is entering FY27 with a structurally improved business, clear of legacy portfolio drag and positioned for innovation-led growth in plasma and hospital segments. IVT is set for a turnaround, but execution on new launches and market stabilization will be critical to sustaining momentum.
- Plasma Platform Anchors Growth: Share gains, innovation, and recurring revenue underpin the company’s core earnings and cash flow profile.
- IVT and Hospital Segments Hold Upside: Turnaround in IVT and margin-rich hospital franchise provide additional growth levers, but require disciplined execution.
- Watch for Upside from Innovation Adoption: Pace of Persona Plus rollout, Percocel Elite launch, and hospital margin expansion are key catalysts for outperformance in FY27.
Conclusion
Hemonetics exits FY26 with its largest headwinds now in the rearview, pivoting toward a cleaner, innovation-driven growth story. Disciplined guidance leaves room for upside, but investors should monitor plasma market dynamics and IVT execution closely as the company enters a new phase of its transformation.
Industry Read-Through
Hemonetics’ results reinforce the durability and pricing power of plasma collection platforms, even amid market noise around inventory and new therapy competition. Yield-enhancing innovation (Persona Plus) is a differentiator, signaling that device makers who can drive efficiency and value for customers will capture incremental share and margin. IVT’s stabilization and renewed growth focus highlight the importance of portfolio rationalization and targeted investment in medtech, with implications for peers navigating similar transitions. Hospital blood management’s margin profile and international expansion point to broader opportunities for companies leveraging integrated, data-driven solutions in acute care settings.